OPRM1
ENSG00000112038
Target class
GPCR
Chromosome
6
Approved drugs
53
Clinical candidates (approved and in development)
69
- Approved drugs
- 53
- Clinical candidates (approved and in development)
- 69
- Chemical probe available
- Yes
- Target name
- OPRM1
- Gene name
- Opioid receptor mu 1
- Gene symbol
- OPRM1
- Protein name
- Mu-type opioid receptor (M-OR-1) (MOR-1) (Mu opiate receptor) (Mu opioid receptor) (MOP) (hMOP)
- MOR1
- MOP
- Gene biotype
- Protein coding
- Gene family
- Opioid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 2.53
- Tissue specificity (Gini)
- 0.938
- Tissue specificity (tau)
- 0.979
- KEGG gene identifiers
- hsa:4988
- Protein interaction confidence
- 0.830543
- Protein interaction partners
- 46
- R-HSA-111885
- R-HSA-202040
- R-HSA-375276
- R-HSA-418594
- R-HSA-6785807
- R-HSA-9022699
- End position
- 154246867
- Start position
- 154010496
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cell projection, axon . Perikaryon . Cell projection, dendrite . Endosome . Note=Is rapidly internalized after agonist binding. .
- SUBCELLULAR LOCATION: [Isoform 12]: Cytoplasm .
- PubMed 10529478
- PubMed 12589820
- PubMed 16580639
- PubMed 7891175
- PubMed 7905839
- PubMed 7957926
- PubMed 9689128
- PubMed 20525224
- Tissue specificity (tau)
- 0.97882
- Expression inequality (Gini)
- 0.93803
Expression in transcripts per million
- Testis
- 2.53
- Brain - Cerebellum
- 1.45
- Brain - Cerebellar Hemisphere
- 0.83
- Brain - Nucleus accumbens (basal ganglia)
- 0.14
- Brain - Hypothalamus
- 0.13
Expression in transcripts per million
- Testis2.53
- Brain - Cerebellum1.45
- Brain - Cerebellar Hemisphere0.83
- Brain - Nucleus accumbens (basal ganglia)0.14
- Brain - Hypothalamus0.13
- Brain - Frontal Cortex (BA9)0.07
- Brain - Cortex0.06
- Brain - Anterior cingulate cortex (BA24)0.04
- Brain - Amygdala0.03
- Brain - Caudate (basal ganglia)0.03
- Pituitary0.01
- Colon - Sigmoid0.01
- Brain - Putamen (basal ganglia)0.01
- Brain - Spinal cord (cervical c-1)0.01
- Fallopian Tube0.01
- Brain - Hippocampus0.01
- Thyroid0
- Uterus0
- Esophagus - Mucosa0
- Brain - Substantia nigra0
- Lung0
- Adrenal Gland0
- Skin - Not Sun Exposed (Suprapubic)0
- Artery - Aorta0
- Bladder0
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0008285
- GO:0048149
- GO:0061358
- GO:0080135
- GO:0005737
- GO:0005783
- GO:0005794
- GO:0005886
- GO:0001965
- GO:0004979
- GO:0005515
drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastric emptying
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastric emptying
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264gas
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: gas
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased cardiac output
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased cardiac output
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased blood pressure
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood glucose
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased convulsions
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased heart rate
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased/decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased/decreased convulsions
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased gastrointestinal transit
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264scratching
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: scratching
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood insulin
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood insulin
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: pain
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastric acid secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastric acid secretion
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased respiratory rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased respiratory rate
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264dyspepsia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dyspepsia
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264sedation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sedation
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264increased/decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased memory
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased body temperature
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased pupil diameter
- pancreas
- nervous system
- respiratory
- renal
- cardiovascular
- gastrointestinal
PubMed 28216264
And 2 more, listed on the interactive page.
decreased gastrointestinal motility
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased gastrointestinal motility
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038hypothermia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hypothermia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038respiratory depression
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: respiratory depression
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038flatulence
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: flatulence
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038increased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased gastrointestinal motility
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038miosis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: miosis
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038sedation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: sedation
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038dyspepsia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dyspepsia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038pupil constriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: pupil constriction
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hOpiate_mu, is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_mu assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceabuse liability
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: abuse liability
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038
Related records
Trials (4,749)
- "NSAIDs vs. Opiates: Which is More Effective in Managing Pain in Mild to Moderate Acute Pancreatitis?
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- [11C]Carfentanil PET Study of GSK1521498
- 0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy
- 2 Dose Neuraxial Morphine for Prevention of PDPH
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial
- 90% Effective Infusion Time of Sufentanil to Prevent Induction Cough: A Biased Coin Sequential Study
- A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
- A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy
- A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
- A 2×2 Factorial Randomized Controlled Trial for ERCP
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.
- A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
- A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
Drugs (96)
- Alfentanil Mu opioid receptor agonist
- Alfentanil hydrochloride Mu opioid receptor agonist
- Alvimopan Mu opioid receptor antagonist
- Anileridine Mu opioid receptor agonist
- Anileridine hydrochloride Mu opioid receptor agonist
- Anileridine phosphate Mu opioid receptor agonist
- Axelopran Mu opioid receptor antagonist
- Axomadol Mu opioid receptor agonist
- Benzhydrocodone Opioid receptors; mu/kappa/delta agonist
- Benzhydrocodone hydrochloride Opioid receptors; mu/kappa/delta agonist
- Bevenopran Mu opioid receptor antagonist
- Buprenorphine Mu opioid receptor agonist
- Buprenorphine hydrochloride Mu opioid receptor agonist
- Butorphanol Mu opioid receptor partial agonist
- Butorphanol tartrate Mu opioid receptor partial agonist
- Cebranopadol Opioid receptors; mu/kappa/delta agonist
- Codeine Opioid receptors; mu/kappa/delta agonist
- Codeine phosphate Opioid receptors; mu/kappa/delta agonist
- Codeine polistirex Opioid receptors; mu/kappa/delta agonist
- Codeine sulfate Opioid receptors; mu/kappa/delta agonist